This is the authors' abstract. We don't add key points for this paper.
CD22 is an attractive target for the development of immunotherapeutic approaches for the therapy of B-cell malignancies. In particular, an m971 antibody-derived, second generation chimeric antigen receptor (CAR) that targets CD22 holds significant therapeutic promise. The key aspect for the development of such a highly-active CAR was its ability to target a membrane-proximal epitope of CD22.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Long et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: